ArticlePharmaceutics2023

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban.

Mohamed F Zaky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.